Abstract
This present industry update covers the period 16 September–15 October 2010, with information sourced from company press releases and websites, regulatory agencies and patent search engines. The imminent patent expiration of a number of key drug patents remains a major concern for many of the large pharmaceutical companies. Consequently, the acquisition of King Pharmaceuticals by Pfizer, whilst still assimilating Wyeth, is likely to set the scene for further sizable mergers and acquisitions to strengthen pipelines and mitigate risk. The regulatory approval of Gilenya™ (fingolimod) by the US FDA represents an exciting and major step forward in the provision of treatment options for multiple sclerosis, and the results of the Phase III clinical study with abiraterone acetate demonstrate a much needed new advancement in the treatment of metastatic, castration-resistant prostate cancer, a stage of the disease that currently has few treatment options and a high mortality rate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
